TXMD TherapeuticsMD, Inc.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The firm also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.
Company profile
Ticker
TXMD
Exchange
CEO
Robert G. Finizio
Employees
Incorporated in
Location
Fiscal year end
Industry (SEC)
Former names
AMHN, Inc., Croff Enterprises Inc, Croff Oil Co
SEC CIK
Corporate docs
IRS number
870233535
TXMD stock data
()
Calendar
9 Aug 19
25 Aug 19
31 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|
| Revenue | 6.08M | 3.95M | 5.09M | 3.47M | |
| Net income | -55.24M | -39.51M | -39.39M | -35.61M | |
| Diluted EPS | -0.23 | -0.16 | -0.17 | -0.16 | |
| Net profit margin | -909% | -1001% | -774% | -1025% | |
| Operating income | -41.64M | -38.11M | -38.12M | -34.36M | |
| Net change in cash | 59.96M | -38.73M | -28.39M | 35.61M | |
| Cash on hand | 182.85M | 122.88M | 161.61M | 190M | |
| Cost of revenue | 1.25M | 762.83K | 950.75K | 699.12K |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 16.1M | 16.78M | 19.36M | 20.14M | |
| Net income | -132.62M | -76.93M | -89.88M | -85.08M | |
| Diluted EPS | -0.59 | -0.37 | -0.46 | -0.49 | |
| Net profit margin | -824% | -458% | -464% | -422% | |
| Operating income | -130.22M | -77.63M | -90.25M | -85.19M | |
| Net change in cash | 34.48M | -4.4M | 66.83M | 13.34M | |
| Cash on hand | 161.61M | 127.14M | 131.53M | 64.71M | |
| Cost of revenue | 2.74M | 2.64M | 4.19M | 4.51M |
Financial data from company earnings reports
Financial report summary
?Competition
Mylan • Pfizer • AMAG Pharmaceuticals • Allergan • VMS • Allergan • Mylan • Amneal Pharmaceuticals • Amneal Pharmaceuticals
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
AccountsTrade, China, comprised, consignment, construed, convenience, display, endorsement, EUR, extinguishment, fall, fullest, HCP, HQ, imply, informationfor, insignificant, noncash, refinancing, SM, sponsorship, suite, tendered, Territory, Theramex, UK, unallocated, upfront, withheld, wrote
Removed:
agency, coupled, determinable, discontinuation, duration, easily, efficacy, expensed, filing, incur, IND, McKesson, month, ongoing, phase, proprietary, reclassified, recruit, reliably, sufficient
Financial reports
10-Q
2019 Q2
Quarterly report
9 Aug 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
27 Feb 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
30 Jul 18
10-Q
2018 Q1
Quarterly report
7 May 18
10-K
2017 FY
Annual report
23 Feb 18
10-Q
2017 Q3
Quarterly report
7 Nov 17
10-Q
2017 Q2
Quarterly report
3 Aug 17
10-Q
2017 Q1
Quarterly report
3 May 17
Current reports
8-K
TherapeuticsMD Announces Second Quarter 2019 Financial Results
6 Aug 19
8-K
Regulation FD Disclosure
9 Jul 19
8-K
Departure of Directors or Certain Officers
21 Jun 19
8-K
Regulation FD Disclosure
10 Jun 19
8-K
TherapeuticsMD and Theramex Enter into Exclusive License and Supply Agreement to Commercialize BIJUVA™ and IMVEXXY® Outside the United States
7 Jun 19
8-K
Regulation FD Disclosure
15 May 19
8-K
TherapeuticsMD Announces First Quarter 2019 Financial Results
6 May 19
8-K
TherapeuticsMD Closes $300 Million Non-Dilutive Term Loan Financing Facility
25 Apr 19
8-K
TherapeuticsMD Signs Binding Commitment Letter for $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners
17 Apr 19
8-K
Regulation FD Disclosure
8 Apr 19
Registration and prospectus
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Jun 19
S-8
Registration of securities for employees
21 Jun 19
424B2
Prospectus for primary offering
2 Aug 18
424B2
Prospectus for primary offering
2 Aug 18
424B5
Prospectus supplement for primary offering
31 Jul 18
424B5
Prospectus supplement for primary offering
31 Jul 18
S-3ASR
Automatic shelf registration
31 Jul 18
25
Voluntary exchange delisting
6 Oct 17
8-A12B
Registration of securities on exchange
6 Oct 17
424B2
Prospectus for primary offering
27 Sep 17
Proxies
DEFA14A
Additional proxy soliciting materials
30 Apr 19
DEF 14A
Definitive proxy
30 Apr 19
DEF 14A
Definitive proxy
27 Apr 18
DEFA14A
Additional proxy soliciting materials
27 Apr 18
DEFA14A
Additional proxy soliciting materials
25 Apr 17
DEF 14A
Definitive proxy
25 Apr 17
DEFA14A
Additional proxy soliciting materials
28 Apr 16
DEF 14A
Definitive proxy
28 Apr 16
DEF 14A
Definitive proxy
30 Apr 15
DEFA14A
Additional proxy soliciting materials
30 Apr 15
Other
CT ORDER
Confidential treatment order
10 Apr 19
CT ORDER
Confidential treatment order
12 Dec 18
CT ORDER
Confidential treatment order
21 Aug 18
UPLOAD
Letter from SEC
6 Feb 17
CORRESP
Correspondence with SEC
31 Jan 17
UPLOAD
Letter from SEC
25 Jan 17
CORRESP
Correspondence with SEC
29 Dec 16
UPLOAD
Letter from SEC
15 Dec 16
EFFECT
Notice of effectiveness
17 Nov 15
CORRESP
Correspondence with SEC
13 Nov 15